Biolase Stock Analysis

BIOL -  USA Stock  

USD 0.77  0.02  2.67%

The new Biolase price pull down could raise concerns from stakeholders as the firm it trading at a share price of 0.77 on 1,727,317 in volume. The company executives were unable to exploit market volatilities in May. However, diversifying your overall positions with Biolase can protect your principal portfolio during market swings. The stock standard deviation of daily returns for 90 days investing horizon is currently 6.6. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Biolase partners.
Continue to Trending Equities.

Search Stock Analysis 

 
Refresh
The Biolase stock analysis report makes it easy to digest most publicly released information about Biolase and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Biolase stock analysis module also helps to analyze the Biolase price relationship with some important fundamental indicators such as market cap and management efficiency.

Biolase Stock Analysis Notes

The company recorded a loss per share of 0.56. Biolase next dividend is scheduled to be issued on the 24th of June 2005. The entity had 201:200 split on the 11th of May 2018. BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. BIOLASE, Inc. was founded in 1984 and is headquartered in Foothill Ranch, California. Biolase operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 135 people. For more info on Biolase please contact Harold Flynn at 949 361 1200 or go to http://www.biolase.com.

Biolase Quarterly Cost of Revenue

5.38 MillionShare

Biolase Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Biolase's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Biolase or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Biolase generates negative expected return over the last 90 days
Biolase has high historical volatility and very poor performance
Biolase has some characteristics of a very speculative penny stock
Biolase has high likelihood to experience some financial distress in the next 2 years
Biolase was previously known as Biolase and was traded on NASDAQ Exchange under the symbol BLTI.
The company reported the previous year's revenue of 22.78 M. Net Loss for the year was (34.21 M) with profit before overhead, payroll, taxes, and interest of 6.17 M.
Biolase currently holds about 17.56 M in cash with (12.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.12.
Biolase has a frail financial position based on the latest SEC disclosures
Latest headline from www.investorsobserver.com: Is BIOLASE Inc Stock About to Get Hot Monday - InvestorsObserver

Biolase Upcoming and Recent Events

Earnings reports are used by Biolase to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Biolase previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report12th of August 2021
Next Earnings Report11th of November 2021
Next Fiscal Quarter End30th of June 2021
Next Fiscal Year End24th of March 2022
Last Quarter Report31st of March 2021
Last Earning Announcement30th of June 2020

Biolase Largest EPS Surprises

Earnings surprises can significantly impact Biolase's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2014-11-04
2014-09-30-0.09-0.080.0111 
2019-08-08
2019-06-30-0.15-0.130.0213 
2018-11-13
2018-09-30-0.17-0.19-0.0211 
View All Earnings Estimates

Biolase SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Biolase prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Biolase investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Biolase specific information freely available to individual and institutional investors to make a timely investment decision.
26th of May 2021
Submission of Matters to a Vote of Security Holders
View
24th of May 2021
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
View
13th of May 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
25th of March 2021
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Results of Operations and Financial Condition
View
17th of March 2021
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
2nd of March 2021
Entry into a Material Definitive Agreement
View
23rd of February 2021
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
16th of February 2021
Unclassified Corporate Event
View

Biolase Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 113.37 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Biolase's market, we take the total number of its shares issued and multiply it by Biolase's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Biolase Profitablity

Biolase's profitability indicators refer to fundamental financial ratios that showcase Biolase's ability to generate income relative to its revenue or operating costs. If, let's say, Biolase is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Biolase's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Biolase's profitability requires more research than a typical breakdown of Biolase's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (73.88) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (79.18) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -0.79.
Last ReportedProjected for 2021
Return on Investment(56.73) (61.21) 
Return on Average Assets(0.50) (0.54) 
Return on Average Equity(3.31) (3.40) 
Return on Invested Capital(0.85) (0.91) 
Return on Sales(0.63) (0.65) 

Management Efficiency

The entity has return on total asset (ROA) of (31.8) % which means that it has lost $31.8 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (234.22) %, meaning that it created substantial loss on money invested by shareholders. Biolase management efficiency ratios could be used to measure how well biolase manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return on Investment is estimated to pull down to -61.21. The value of Return on Average Assets is estimated to pull down to -0.54. Biolase Revenue to Assets are relatively stable at the moment as compared to the past year. The company's current value of Revenue to Assets is estimated at 1.56. Total Assets Per Share is expected to hike to 0.86 this year, although the value of Net Current Assets as percentage of Total Assets will most likely fall to 29.16.
Last ReportedProjected for 2021
Book Value per Share 0.16  0.17 
Enterprise Value over EBIT(3.00) (3.24) 
Enterprise Value over EBITDA(2.71) (2.93) 
Price to Book Value 3.87  5.72 
Tangible Assets Book Value per Share 0.62  0.64 
Enterprise Value37.5 M43.4 M
Tangible Asset Value38.1 M39.8 M

Technical Drivers

As of the 17th of June 2021, Biolase shows the risk adjusted performance of (0.010536), and Mean Deviation of 4.11. Biolase technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to break down and interpolate data for nineteen technical drivers for Biolase, which can be compared to its rivals. Please confirm Biolase coefficient of variation, treynor ratio, as well as the relationship between the Treynor Ratio and semi variance to decide if Biolase is priced correctly, providing market reflects its regular price of 0.77 per share. As Biolase is a penny stock we also strongly suggest to validate its total risk alpha numbers.

Biolase Price Movement Analysis

The output start index for this execution was fourty-nine with a total number of output elements of twelve. The Exponential Moving Average is calculated by weighting recent values of Biolase more heavily than older values. View also all equity analysis or get more info about exponential moving average overlap studies indicator.

Biolase Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Biolase insiders, such as employees or executives, is commonly permitted as long as it does not rely on Biolase's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Biolase insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Biolase Predictive Daily Indicators

Biolase intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Biolase stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Biolase Forecast Models

Biolase time-series forecasting models is one of many Biolase's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Biolase's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Biolase Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Biolase stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Biolase shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Biolase. By using and applying Biolase Stock analysis, traders can create a robust methodology for identifying Biolase entry and exit points for their positions.
Last ReportedProjected for 2021
Operating Margin(33.21) (35.83) 
EBITDA Margin(0.61) (0.63) 
Gross Margin 0.27  0.30 
Profit Margin(0.74) (0.76) 
BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. BIOLASE, Inc. was founded in 1984 and is headquartered in Foothill Ranch, California. Biolase operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 135 people.

Current Biolase Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Biolase analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Biolase analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
2.0Buy2Odds
Biolase current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Biolase analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Biolase stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Biolase, talking to its executives and customers, or listening to Biolase conference calls.
Biolase Analyst Advice Details

Biolase Stock Analysis Indicators

Biolase stock analysis indicators help investors evaluate how Biolase stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Biolase shares will generate the highest return on investment. By understating and applying Biolase stock analysis, traders can identify Biolase position entry and exit signals to maximize returns.
Quick Ratio1.97
Fifty Two Week Low0.2500
Revenue Growth-16.30%
Average Daily Volume Last 10 Day5.58M
Shares Short Prior Month9.48M
Average Daily Volume In Three Month5.58M
Shares Percent Shares Out5.53%
Gross Margins27.10%
Forward Price Earnings-7.53
Short Percent Of Float5.61%
Float Shares146.55M
Fifty Two Week High1.5100
Fifty Day Average0.7126
Enterprise Value To Ebitda-6.09
Two Hundred Day Average0.7790
Enterprise Value To Revenue4.82
Continue to Trending Equities. Note that the Biolase information on this page should be used as a complementary analysis to other Biolase's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.

Complementary Tools for Biolase Stock analysis

When running Biolase stock analysis, check to measure Biolase's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biolase is operating at the current time. Most of Biolase's stock examination focuses on studying past and present price action to predict the probability of Biolase's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Biolase's price. Additionally, you may evaluate how the addition of Biolase to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
The market value of Biolase is measured differently than its book value, which is the value of Biolase that is recorded on the company's balance sheet. Investors also form their own opinion of Biolase stock's value that differs from its market value or its book value, called intrinsic value, which is Biolase's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biolase's market value can be influenced by many factors that don't directly affect Biolase underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biolase's stock value and its price as these two are different measures arrived at by different means. Investors typically determine Biolase value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biolase's stock price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.